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TOO MUCH MEDICINE
Mapping the drivers of overdiagnosis to potential
solutions
Thanya Pathirana and colleagues explore strategies to tackle the problem of too much medicine
Thanya Pathirana PhD scholar, Justin Clark senior information specialist, Ray Moynihan senior
research fellow
Center for Research in Evidence Based Practice, Bond University, Australia
In our collective enthusiasm to diagnose and treat disease, a
growing body of evidence indicates that we may often be doing
too much of a good thing.1-5 “Overdiagnosis” is now widely
recognised to occur when people are labelled with or treated
for a disease that would never cause them harm—often as a
result of undergoing screening—and it can lead to the overuse
of further tests and treatments.2 6 One example is thyroid cancer,
with estimates that over 500 000 people may have received
overdiagnoses across 12 countries in the past two decades,
leading to unnecessary surgery and lifelong medication for
many.7
Overdiagnosis is a challenge to the sustainability of human
health and health systems. Its causes—including the best of
intentions—are as complex and multifaceted as the potential
solutions.8-13 As part of the preparation for a possible national
action plan in Australia, we searched the literature for causes
of and responses to overdiagnosis. Here we provide the first
comprehensive analysis of the possible drivers of overdiagnosis
and related overuse, mapped to potential solutions.
Searching the literature
Our approach to the initial and updated PubMed searches of the
literature is outlined in the data supplement (see bmj.com) and
yielded a total of 36 articles, to which we added a further five
(fig 1⇓). We included articles that explicitly discussed possible
drivers and potential responses or solutions to the problem of
overdiagnosis. We included original research as well as opinion,
commentary, and analysis articles. Reflecting the relatively
recent and growing interest in overdiagnosis, the vast majority
were published since 2013, with generally increasing numbers
each year (rising from three before 2013 to nine in 2016 and
four in 2017 up until July).
Given the limitations of the literature to date, we couldn’t assess
the quality of evidence behind each claim in each article, so this
is not a systematic review. The vast majority of included articles
are analyses or commentaries, with a small number of important
exceptions, including a systematic review. Although discussion
of drivers and solutions in many of the included analysis pieces
were informed directly by empirical evidence, including
systematic reviews the original studies are not included here,
as they did not explicitly discuss drivers or solutions in ways
captured by our search strategy. The body of empirical evidence
highlighting the problem of overdiagnosis is growing, but a
systematic review is beyond the scope of this article. Similarly,
although analysing the complex inter-relation between
overdiagnosis and the overuse it drives14 is vitally important, it
is outside the reach of this article.
The map arising from our analysis is broad but not
definitive—potential causes or solutions might not yet have
been identified in the literature, and breadth might come at the
cost of depth. In addition, our search was based in medicine,
and a wider analysis might identify important sociological
investigations of medicalisation15 resulting in different
conceptions of the problem, drivers, and solutions. Importantly
no strict or established criteria for what defines a driver or a
solution exist, so our decisions about inclusion and mapping
are open to discussion. Moreover, individual items could in
some cases map to more than one domain. We have made no
attempt to integrate this map with the extensive science of
behaviour change16 or to specify potential actors to work on
solutions, but hope that others will pursue this work.
What’s driving overdiagnosis?
Possible drivers of overdiagnosis span five domains: culture,
the health system, industry, professionals, and patients and the
public (table 1⇓; fig 2⇓). In this section, we offer a narrative
summary of some important drivers that appear most commonly
in the literature.
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Interest is growing in tackling the problems of overdiagnosis and overtreatment
Possible drivers and potential solutions arise across five inter-related domains: culture, the health system, industry and technology,
healthcare professionals, and patients and the public
More work is needed to develop and evaluate interventions aimed at preventing overdiagnosis
Raising public awareness of overdiagnosis is a priority
Culture drivers
Popular deep seated beliefs that in healthcare “more is better”
and “new is better” are often cited as drivers of unnecessary
testing and overdiagnosis.3-24 Related to this is a strong collective
faith in the benefits of screening the healthy and making an
early diagnosis, arising in part from our fears of a serious disease
being missed or a diagnosis made too late.3-29 As Welch,
Schwartz, and Woloshin argue in their 2011 book
Overdiagnosed, which draws on a wealth of empirical evidence,
“early diagnosis is a double edged sword,” with the potential
to help but also hidden danger: “the detection of abnormalities
that are not destined to ever bother us.”2 Fears of uncertainty,
ageing, death, and disease also collectively contribute to this
culture of too much medicine.8-47
Health system drivers
Expanding disease definitions, which identify more previously
healthy people as “sick,” are commonly cited as a driver of
overdiagnosis.3-47 Health professionals and hospitals frequently
have financial incentives to perform more investigations or
treatments for their patients, favouring increased and sometimes
unnecessary care. Moreover, a system based on fee for service
may lead to time restraints during consultations with inadequate
time available for shared decision making or the complex
explanation of the counterintuitive problem of overdiagnosis.4-32
As Malvinder Parmar said, “the current fee-for-service system
does not compensate for a comprehensive explanation to the
patient why a test is not required.”9 Current quality measures
in health systems may lack emphasis on preventing
overdiagnosis or overuse and instead may indirectly promote
these problems.3-21
Industry and technology drivers
The most important driver in this domain is the use and
promotion (to clinicians and the public) of increasingly sensitive
tests, leading to detection—often incidentally—of minor
“abnormalities,” which may be of uncertain clinical significance
and can cause overdiagnosis.3-47 Industry promotion can also
include the funding of patient and advocacy groups.8-28 As Eric
Coon and colleagues point out in their well reasoned and
evidence based exploration of potential drivers of overdiagnosis
among children, “Advertisements capitalize on our fear of
undiagnosed disease and urge us to see our doctor for testing .
. . Once considered unbiased, third party advocacy groups are
often used to deliver the same message.”17 Commercial
imperatives and conflicts of interest, including financial or
reputational conflicts of interests of those involved in guideline
panels that expand disease definition, are also cited as a
concern.3-47
Professional drivers
Many authors argue that health professionals are driven to
practise defensive medicine owing to their fear of litigation
arising from a purported omission.3-41 Closely related is the
doctor’s fear of missing a diagnosis, also commonly cited as a
potential driver of overdiagnosis.3-29 Health professionals’ unease
with dealing with an uncertain diagnosis may lead them towards
overtesting and overdiagnosis. This lack of professional
confidence and knowledge of harms,8-30 as well as the tendency
to routinely diagnose or “do something” may arise from flaws
in medical training,9-23 with underemphasis on patient preferences
and overemphasis on diagnosis.20-47
Patient and public drivers
While important, the results of our analysis indicate that this
domain has received less attention in the literature, although it
clearly overlaps with the culture domain. A number of authors
point to a perception that many people have a lack of knowledge
about the limits to, and harms of, medicine8-47 and suggest that
patients tend to over-rely on tests, including as a means of
reassurance.8-28 Others identify patient expectations that
clinicians will “do something” as a potential driver.9-21
What are the potential solutions?
Many of the potential solutions commonly identified in the
literature map closely to explicit drivers, with some important
exceptions (table 1⇓). For some drivers, such as the increasing
complexity and fragmentation of care, specific relevant solutions
were not identified. Other drivers showed considerable overlap,
both within and across domains. The health system domain, for
example, overlaps with the industry and technology domain,
where enhanced government regulation of commercial
promotion or health technology evaluation clearly falls primarily
to policy makers. We made every attempt to link drivers to
potential solutions.
Culture solutions
Public awareness and education campaigns are needed to
challenge beliefs that in healthcare “more is better” 9-26 and to
promote a more healthy scepticism about the benefits and
potential harms of early diagnosis.2-22 Arguably, initiatives like
The BMJ’s Too Much Medicine campaign,48 Choosing
Wisely,49JAMA Internal Medicine’s “Less is more,”50 and Health
News Review51 are moving in this direction. Given the powerful
role that media can play in shaping public beliefs, strategies to
improve media reporting on overdiagnosis are needed.2-28
Health system solutions
Reforming incentives for professionals and healthcare
organisations to reward the quality rather than quantity of care
is commonly cited as a key way to tackle the problem of too
much medicine.3-30 Some authors also cite the need for new
evidence informed frameworks to be used when disease
definitions are changed,52 with calls for changes to disease
terminology and new expert panels that are more widely
representative and have reduced or minimal conflicts of
interests.3-37 An influential group convened by the US National
Cancer Institute is among those advocating changes to disease
terminology for indolent lesions.26 Quality indicators and
guidelines are also targeted for reform, to tackle any incentives
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for medical excess, as well as include new measures of
overdiagnosis and overuse.4-38 More targeted screening
programmes that might, for example, limit some screening to
well defined high risk populations9-39 and mandated strategies
to inform patients of the benefits and harms of screening3-36 are
among potential solutions for minimising the risks of
overdiagnosis associated with screening. The 2016 systematic
review of studies aimed at reducing low value care and underuse
across different parts of the health system found that
interventions using multiple strategies and targeting the roles
of both clinicians and consumers had the greatest potential.10
Industry and technology solutions
More rigorous evaluation of the effects of both new and existing
diagnostic technology on health outcomes is commonly
recommended3-39 as a key solution to the problem of increasingly
sensitive tests that detect “abnormalities” of uncertain clinical
significance. Drawing from the field of ecological economics
to frame overdiagnosis as overconsumption , Hensher and
colleagues call for “a more rigorous application of the
precautionary principle” in technology assessment to avoid
giving “potentially harmful overuse the benefit of the doubt.”12
Other potential solutions include stronger regulation of the
advertising of new tests and treatments to the public and health
professionals30 and paying greater attention to managing and
reducing conflicts of interest with industry.47
Professional solutions
The need to tackle the medicolegal concerns regarding missing
or delaying a diagnosis was one of the key solutions discussed
in the literature.3-47 Another recommended solution is updating
current medical curriculums and continuing medical education
to include overdiagnosis and overuse, for both students and
practitioners.3-47 As future practitioners, students must be taught
to “look always for the possibility of harm alongside that of
benefit.”25 This is vital because, according to Eric Coon and
colleagues, “if physicians are not aware of the potential harms
of overdiagnosis, patients and families cannot be expected to
appreciate them either.”17
Patients and the public solutions
Widespread awareness campaigns to inform and educate patients
and the public on harms as well as benefits of screening and
treatment options are commonly cited as essential to tackling
overdiagnosis,3-47 echoing and overlapping with solutions we
have classified in the cultural domain. Another frequently
recommended solution was promoting shared decision making
as a response to several key drivers in this domain.13-47 In
addition, several authors proposed the need for prioritising
treatment options such as watchful waiting or active
surveillance, where appropriate.3-35
Where to from here?
We have attempted to retrieve, analyse, and summarise the
existing literature on drivers and responses to overdiagnosis
and related overuse. Many authors have identified a wide range
of potential solutions across five inter-related domains of culture,
the health system, industry and technology, professionals, and
patients, with the ultimate shared aims to prevent harm, reduce
waste, and redirect resources to treating and preventing unmet
need in healthcare. The results of this analysis emphasise the
need for more evidence about the problem, increased evaluation
of potential solutions, and enhanced education across all sectors,
to help wind back the harms of too much medicine effectively,
safely, and fairly.
As part of multiple level strategies, in our view the most urgent
need is to generate accessible evidence based information and
educational materials about overdiagnosis for the public,
professionals, and decision makers—both general information
and condition specific. Tackling the gamut of financial
incentives that drive unnecessary diagnoses and strengthening
regulatory processes to enhance evaluation of new and existing
diagnostic technology are two more solutions, as difficult as
they are desirable. Reforming inappropriately widened disease
definitions is arguably the most challenging but most important
solution.
We strongly encourage critical responses to this analysis,
offering alternative interpretations or missed drivers or solutions.
Indeed optimising societies’ responses to medical excess will
require broader thinking and analysis outside medicine—from
such places as economics and sociology.
As the evidence base around this problem continues to grow,
so do attempts to translate that evidence into action. In Norway,
a position paper from the College of General Practice calls for
action53; in Australia, major influential professional and
consumer organisations are launching a national plan; and in
Canada, the Quebec Medical Association is already
implementing a province-wide strategy. Building on existing
initiatives, we hope this analysis will help offer a suite of
possible solutions to those seeking to reduce iatrogenic harm
and enhance health system sustainability.
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Table
Table 1| Possible drivers of and potential solutions to overdiagnosis
Potential solutionsPossible drivers
Culture
Public awareness, information, and education campaigns challenging
beliefs9-24-26
Beliefs: “More is better,” “new is better,” “early is better,” “wants to
know/screen”—even if currently healthy, imperative of possibility (we
have to test because we can)3-17-24
More healthy scepticism on the benefits of early diagnosis especially
in populations less likely to benefit2-22
Faith in early diagnosis or detection and prevention is better than cure,
fear of diagnosis missed or made too late3-27-29
Address intolerance of uncertainty22Intolerance of uncertainty and error8-28-30
NAMedicalisation of life; fear of ageing, sickness, or death9-22-25-31
Improve media reporting, journalist training, campaigns about
overdiagnosis and overuse2-28
Biased reporting by media—eg, reporting lack of care more than
underdiagnosis and overdiagnosis8-23
Health system
Reform incentives from quantity to quality3-30Financial incentives for more tests, treatments, and diagnoses,
including fee for service and not enough time to talk
4 8-11-21-23-32
Unique market system within healthcare; third party payer can shield
patient from cost*4 23
Corporate health insurance packages for healthy adults18
Supplier induced demand12
Reform process of disease definition and constitution of guideline
panels–fewer conflicts of interest, more broadly representative3-34
Change terminology for indolent lesions—eg, labelling innocuous
cancers as “indolent lesion of epithelial origin” rather than cancer11-35-37
Avoid or rename certain disease labels27
Expanding disease definitions3-33
Reform performance and quality measures and develop new measures
of overdiagnosis and overuse4-38
Quality measures that encourage doing more3-21
Lack of focus of quality and performance indicators on overuse and
overmedicalisation
17
Reform guidelines on tests and treatments:
Include what’s not recommended4-23
Review and include harms and risk of overdiagnosis6-30
Avoid conflict of interests in guideline panels, use evidence11 13
Guidelines4-32
Reform or limit screening:
Avoid certain tests or screening tests
11 35
Less frequent screening tests11-35
Targeted screening tests (eg, limit screening to well defined high risk
population)9-35-37-40
Inform patients of benefits and harms of screening3-36
Raise threshold for “positive” screen or recall and biopsy26-39
Change radiological advice35
Screening3-33
NAIncreasing complexity† and fragmentation‡ of care and loss of
continuity of care4-41
More research on:
drivers of overdiagnosis and overuse9 23




deliberative and qualitative methods (including community juries) to
inform policy and other decisions23-36
evaluating responses to overuse, including communication23
NA
Multicomponent interventions tackling patient and provider roles, to
reduce overuse and low value care10
NA
Industry§ and technology
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Better regulate advertising30Industry promotion of tests and treatments to professionals and public:
Advertising (including direct to consumer marketing), promotion,
influence using the media to generate demand for diagnosis3-29
Industry funding of patient and advocacy groups8-28
Industry wants to develop better diagnostic technology—technological
arms race19-24
Better evaluation of diagnostic technology:
Better evaluation of new and existing diagnostic technology
23-43
Evaluate effects of test-treatment strategies on outcomes, not just test
performance alone, more caution in treating incidentalomas3-34
Better identify harmful v benign abnormalities3 27
Increasing specificity of tests at the cost of slightly decreased sensitivity39
Include patient voice in development, assessment, implementation,
and use of technology24
Strengthen health technology assessments and cost effectiveness
analyses12
Diagnostic tests with increased sensitivity:
New technology captures ever smaller “abnormalities”or iincidental
findings3-33
Changes nature and prevalence of disease20 24
Feedback loop: diagnosing milder cases, high prevalence, better
outcomes, more tests and treatments—illusion of progress
3-25
Declare, reduce, exclude conflicts of interest19Medicine as a business and conflicts of interest
Commercial and corporate clinics—self referral, vertical integration3 8
Commercial and other conflicts of interest3-27
Professional conflicts of interest, specialist societies protecting or
expanding turf3-9
Toxic combination of vested interests and good intentions25
Supply-sensitive care17
Better evaluation of changes to (expansion of) disease definitions34Industry interest in expanding markets, including financial ties to those
setting diagnostic thresholds3-32
Professionals
Tackle and reform drivers of litigation and defensive medicine3-22Fear of litigation or defensive medicine3-19-23 27-30-41
Critical thinking and comfort with uncertainty (eg, with a period of active
surveillance, watchful waiting)12-35
Fear of missing disease or decision regret3-29
Educational curricula and information materials on overdiagnosis and
overuse for students and professionals3-45
Flaws in training:
Hard to do nothing rather than something9-23
Overemphasis on diagnosis
20
Problem based learning approach leads to shotgun approach to
diagnosis, rewards unusual or rare diagnoses, and contributes to
overtesting and overdiagnosis, with an emphasis on avoiding omission
errors4-41
Poor knowledge of patient preference and shared decision making 23
Improper weighting of absolute v relative risk8-44
Lack of professional self confidence or knowledge of harms8-30
Interventions to reduce overuse and overdiagnosis:
Multicomponent interventions tackling patient and provider roles (eg,
clinician education with decision support or feedback) to reduce overuse
and low value care10
Using minimally invasive techniques to eventually replace surgery for
low risk tumours (eg, low staged lung tumours)39
Clinical decision support and performance feedback10 13
Compare practices with peers (eg, prescribing, referrals, tests)13
Deprescribing44
NA
Reduce over-reliance on tests
Anticipate consequences of discovering abnormalities11
More time with patient to order less tests30 46
Tools to promote discussion with patients on why test might not be
needed13
Don’t use diagnostic labels unless needed33
Consider stepped or slower diagnosis17 33
Overusing or over-reliance on tests9 13:
Using tests to close consultation13
Chasing incidental findings and test outcomes of no or doubtful
significance9
Chart overload syndrome (order test to avoid reading thick chart)9
Specialists ordering tests before clinical appointment assessments9
Specialists suggesting unnecessary tests to primary provider, especially
during short consultation or in corridor9
Incomplete information of test ordering requests9
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Radiologists suggesting further imaging studies (self referral) when
they don’t have complete clinical information about patient9
Tests express “care” to patients and families, whereas watchful waiting
deemed uncaring17
“Better to know” bias that may not be warranted8
Too much focus on surrogate markers20
Patients and public
NAOver-reliance on tests, including for reassurance8-28
Shared decision making13-21-23-46NA
Information and education campaigns, with accessible evidence, on
the benefits and harms of interventions, including screening, from
unconflicted sources3 8-10-46
Lack of knowledge or confidence about limits and harms of medicine8 23
Research and promote doing nothing, watchful waiting, or active
surveillance as legitimate options, where appropriate3-35
Expectation that clinicians will “do something”9-21
Some responses may map to more than one driver. NA=not applicable. *In most markets, costs are constrained by consumers’ ability to pay; in health care,
services are ordered by physicians, who are unaffected by cost, and received by patients, who often bear only a portion of the cost. †Leading to test duplication,
polypharmacy, and redundant opinions owing to one person seeking advice from several physicians. ‡When patients are forced or indirectly encouraged to seek
care through an inappropriate or inefficient avenue. For instance, all too frequently, the most expeditious route to urgent, but not emergent, care is through an
emergency department. §Industry includes for-profit drug and device companies and commercial or corporate medicine providers. ¶Where higher capacity in the
form of hospital beds and imaging modalities drives medical use and inevitably uncovers patient abnormalities
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Figures
Fig 1 Flow diagram
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Fig 2 Overdiagnosis and related overuse. Mapping possible drivers to potential solutions. COI=conflict of interest;
OD=overdiagnosis; OU=overuse.
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